CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.21442644

Available online at: http://www.iajps.com Review Article

SELF-MEDICATION AND OTC DRUG USE: GLOBAL REGULATION, CONSUMER BEHAVIOUR, AND FUTURE DIRECTIONS

Shivam Sharma[1], Jyoti Pandit[2], Krati[2], Swati Pandey[2], Esha Vatsa[3*], Amandeep Singh[4]

[1]Student, School of Pharmaceutical Sciences (Formerly Himgiri Zee University), Jigyasa University, Dehradun, Uttarakhand, India

[2]Assistant Professor, School of Pharmaceutical Sciences (Formerly Himgiri Zee University), Jigyasa University, Dehradun, Uttarakhand, India

[3*]Associate Professor, School of Pharmaceutical Sciences (Formerly Himgiri Zee University), Jigyasa University, Dehradun, Uttarakhand, India, bhardwajesha1502@gmail.com

[4]Professor, School of Pharmaceutical Sciences (Formerly Himgiri Zee University), Jigyasa University, Dehradun, Uttarakhand, India

Abstract:

Over-the-Counter (OTC) drugs have become integral to modern healthcare, offering patients autonomy in managing minor conditions while reducing systemic costs. This paper provides a comprehensive review of OTC regulation, clinical risks, consumer behaviours, and emerging innovations. Comparative analysis highlights the United States' dual-pathway system modernised under the CARES Act, the European Union's harmonised directives, Japan's tiered "switch OTC" model, and Latin America's heterogeneous enforcement. India's reliance on statutory exclusions and Ayurvedic/nutraceutical loopholes underscores the urgent need for a formal OTC category. Empirical survey data (N = 40) reveal paradoxical consumer behaviours: strong vigilance in checking expiry dates but frequent misuse of prescription-only drugs such as Diclofenac Sodium. The rise of digital health platforms and e-pharmacies further reshapes OTC access, offering convenience but raising risks of counterfeit products, reduced pharmacist interaction, and data privacy concerns. Pharmacists are emphasised as critical gatekeepers, while special populations—including children, the elderly and pregnant women—require targeted safeguards. In conclusion, OTC drugs represent both an opportunity and a challenge. Their safe integration demands coordinated strategies: formalising OTC regulation in India, strengthening pharmacist-led counselling, embedding pharmacovigilance systems, regulating digital health platforms, and harmonising global standards for herbal and nutraceutical formulations. These measures are essential to ensure that OTC drugs fulfil their promise of accessible, affordable, and safe healthcare worldwide.

Keywords: *Over-the-Counter (OTC) Drugs, Self-Medication, Regulatory Frameworks, Pharmacovigilance, Digital Health & E-Pharmacy, Consumer Behaviour and Herbal and Nutraceutical Products*

Corresponding author:
Esha Vatsa,
Associate Professor,
School of Pharmaceutical Sciences (Formerly Himgiri Zee University),
Jigyasa University, Dehradun, Uttarakhand, India,
E Mail:: bhardwajesha1502@gmail.com

QR CODE

Please cite this article in press ***Esha Vatsa*** *et al.,* ***Self-Medication And Otc Drug Use: Global Regulation, Consumer Behaviour, And Future Directions****, Indo Am. J. P. Sci, 2026; 13(07).*

1. INTRODUCTION & BACKGROUND:

Over-the-Counter (OTC) drugs represent a cornerstone of modern healthcare delivery, enabling patients to access therapeutic agents without the need for a physician's prescription. This accessibility supports self-care for minor, self-limiting conditions, reduces unnecessary clinical consultations, and alleviates the burden on overstretched healthcare systems [1]. However, the convenience of OTC medicines is accompanied by significant risks, including irrational self-medication, drug-drug interactions, and the potential acceleration of antimicrobial resistance [3].

Globally, the regulatory frameworks governing OTC drugs vary widely. In the United States, the Food and Drug Administration (FDA) employs a dual-pathway system comprising the New Drug Application (NDA) process and the OTC Drug Monograph System, recently modernised under the CARES Act of 2020 [5]. In contrast, India lacks a formal statutory definition of OTC drugs, relying instead on exclusions from Schedules H, X, G, and K of the Drugs and Cosmetics Rules, 1945. This absence of a distinct OTC category has led to widespread commercialisation of Ayurvedic and nutraceutical formulations under regulatory loopholes, further complicating the self-medication landscape [6]. Beyond regulatory considerations, the role of pharmacists is increasingly recognised as pivotal in guiding safe OTC use. Pharmacists serve as frontline healthcare professionals, offering counselling on dosage, drug interactions, and contraindications, thereby mitigating risks associated with unsupervised consumption [7]. The rise of digital health platforms and e-pharmacies has further transformed consumer access, enabled online purchases and mobile app-driven self-care decisions, but also raised concerns about counterfeit products and inadequate patient counselling [13].

Special populations—including children, the elderly, and pregnant women—face heightened risks from inappropriate OTC use due to physiological vulnerabilities and polypharmacy concerns. Moreover, the growing market for nutraceuticals and herbal OTC products underscores the need for harmonised global regulation, as these agents often bypass conventional safety and efficacy evaluations [12]. In summary, OTC drugs embody both opportunity and challenge. While they democratize healthcare access and reduce systemic costs, their safe integration requires robust regulation, pharmacist-led counselling, digital health safeguards, and targeted public health literacy campaigns. This paper explores these dimensions through a comprehensive analysis of global regulatory frameworks, consumer behaviours, and future innovations in self-medication practices.

Figure 1. Global Overview of OTC Drug Regulation

Regulatory approaches to Over-the-Counter (OTC) drugs vary widely across countries, reflecting differences in legal frameworks, pharmacist involvement, and enforcement practices.



Note: The map is a simplified representation intended for illustrative purposes.

2. GLOBAL REGULATORY MECHANISMS

2.1 United States Food and Drug Administration (FDA) Dual-Pathway Architecture

The United States employs a highly structured two-tier system managed by the Centre for Drug Evaluation and Research (CDER) under the Food and Drug Administration (FDA). A therapeutic molecule must be classified as prescription-only unless empirical evidence demonstrates that it can be safely self-administered by lay consumers. OTC drugs may enter the market either through the OTC Drug Monograph System or the New Drug Application (NDA) process, with the former offering rapid commercialisation for time-tested ingredients and the latter requiring extensive clinical data submission [5].

2.2 OTC Drug Monograph System and GRASE Status

The OTC Drug Monograph System functions as a regulatory "cookbook," defining permissible active ingredients, dosage concentrations, and labelling requirements. Drugs conforming to these monographs are designated as Generally Recognised as Safe and Effective (GRASE), bypassing individual pre-market approval. This system ensures consistency across therapeutic categories such as antacids, sunscreens, and non-narcotic analgesics [9].

2.3 System Modernisation via the CARES Act (Section 505G)

The Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 modernised the monograph system by replacing the outdated public rulemaking process with an agile Administrative Orders Process. This reform allows the FDA to rapidly update labelling requirements, withdraw unsafe ingredients, and approve new OTC Monograph Order Requests (OMORs), thereby enhancing regulatory responsiveness [9].

.

2.4 European Union Regulatory Framework

In the European Union (EU), OTC drugs are governed under Directive 2001/83/EC, which establishes a harmonised framework for medicinal products. Drugs are classified as prescription-only unless they meet criteria for safe self-administration, including low toxicity, minimal risk of misuse, and clear labelling. Member states maintain national lists of OTC medicines, but harmonisation ensures cross-border consistency. Pharmacists play a critical role in counselling, with many EU nations mandating pharmacist oversight even for OTC sales [10].

2.5 Japan's Switch OTC System

Japan employs a unique "switch OTC" system, wherein prescription drugs may be reclassified as OTC after sufficient post-marketing safety data are accumulated. The Ministry of Health, Labour and Welfare (MHLW) oversees this process, supported by the Pharmaceuticals and Medical Devices Agency (PMDA). Categories of OTC drugs are stratified into Class 1 (high-risk, pharmacist-only), Class 2 (moderate risk, pharmacist guidance recommended), and Class 3 (low risk, general sale). This tiered approach balances accessibility with patient safety [11].

2.6 Latin American Perspectives

Latin America presents a heterogeneous regulatory landscape. In countries such as Brazil and Mexico, OTC drugs are widely available, but enforcement of prescription-only categories remains inconsistent. A multicentre study across six Latin American nations revealed a high prevalence of self-medication, particularly with antibiotics and analgesics, driven by economic constraints and limited healthcare access [2]. Regulatory authorities face challenges in curbing irrational use while maintaining affordability and accessibility



Table 1. Comparison of OTC Regulatory Frameworks

Country	Regulatory Authority	OTC Classification	Pharmacist Role	Special Features
USA	FDA	Monograph + NDA	Moderate	CARES Act
European Union	EMA	Directive 2001/83/EC	Mandatory counselling	Harmonised regulation
Japan	PMDA	Class 1–3 Switch OTC	Strong	Risk-based classification
India	CDSCO	No formal OTC category	Variable	Schedule exclusion
Brazil	ANVISA	Defined OTC	Moderate	High self-medication
Mexico	COFEPRIS	Defined OTC	Moderate	Enforcement challenges

3. THE CLINICAL CONUNDRUM: SELF-MEDICATION RISKS & BENEFITS

3.1 Global Prevalence and the Problem of Antibiotic Resistance

Self-medication offers convenience and immediate relief for minor illnesses, but irrational use introduces systemic risks. A critical global concern is the widespread, unsupervised consumption of antibiotics. In many developing nations, weak enforcement at retail counters enables easy access to antimicrobials, leading to subtherapeutic dosing, masking of severe pathologies, and accelerating microbial resistance [4]. The World Health Organisation (WHO) has repeatedly emphasised that irrational antibiotic use is a leading driver of antimicrobial resistance, now recognised as one of the greatest threats to global health security [8].

3.2 The Economics of Substitution: The Accessibility Effect

Economic utility models suggest that patients substitute professional consultations with OTC purchases when physician visits are costly or inaccessible. Evidence from the Korea Health Panel Survey demonstrates that mandatory separation of prescribing and dispensing increases retail pharmacy visits, thereby driving up concurrent purchases of both prescription and OTC drugs [5]. This "accessibility effect" highlights how structural healthcare policies can inadvertently shape self-medication behaviours.

3.3 OTC Drug Safety and Pharmacovigilance

Despite their widespread availability, OTC drugs are not exempt from adverse drug reactions (ADRs). Pharmacovigilance systems, traditionally focused on prescription medicines, must expand to include OTC products. The WHO's International Drug Monitoring Programme encourages member states to collect ADR data for OTC drugs, particularly analgesics, antacids, and cough/cold remedies, which are frequently implicated in misuse (WHO, 2000). National pharmacovigilance centres in India and the EU have begun integrating OTC safety reporting, but underreporting remains a challenge due to consumer perceptions that OTC drugs are inherently risk-free [10].

3.4 Special Populations at Risk

Certain demographic groups face heightened vulnerability from inappropriate OTC use:

- **Children:** Paediatric populations are at risk from cough syrups and antipyretics, where dosing errors can lead to toxicity.
- **Elderly:** Polypharmacy in geriatric patients increases the likelihood of drug-drug interactions, particularly with NSAIDs and antihistamines.
- **Pregnant and Lactating Women:** OTC analgesics and herbal supplements may pose teratogenic or lactation-related risks, often underestimated by consumers.

Targeted education campaigns and pharmacist-led counselling are essential to safeguard these populations, ensuring that accessibility does not compromise safety [12].

Table 2. Advantages and Risks of OTC Medicines

Advantages	Risks
Easy accessibility	Self-medication
Reduced physician visits	ADRs
Cost-effective	Drug interactions
Better self-care	Antibiotic resistance
Convenience	Misdiagnosis
Faster treatment	Delay in professional care

4. EXPLORATORY MARKET RESEARCH METHODOLOGY & RESULTS

4.1 Survey Instrument and Participant Selection

To capture contemporary consumer behaviours, an exploratory survey was conducted using a standardised digital questionnaire. The instrument was designed to evaluate consumption patterns, literacy regarding product parameters, and awareness of pharmaceutical safety boundaries. A sample size of **N = 40 individuals** was selected,

representing a mix of urban and semi-urban populations in Dehradun, Uttarakhand. The survey provided an empirical snapshot of retail drug interaction behaviour, reflecting both traditional pharmacy practices and emerging digital health trends.

4.2 Empirical Data Presentation and Statistical Breakdown

The survey results revealed diverse consumer practices:

- **51.22%** purchased medicines without prescriptions, indicating widespread self-medication.
- **90.00%** checked expiry dates, suggesting strong awareness of product safety.
- **80.00%** maintained domestic storage of medicines, aligning with global self-care norms.
- **45.00%** preferred Diclofenac Sodium for headaches, despite its Schedule H classification in India.
- **65.00%** were familiar with the concept of drug interactions, though **35.00%** lacked awareness.

These findings highlight both encouraging safety behaviours and persistent vulnerabilities in consumer literacy.

4.3 Critical Analysis of Survey Insights

The survey underscores a paradox: while consumers demonstrate vigilance in checking expiry dates and maintaining home first-aid kits, significant gaps remain in understanding drug scheduling and risks. The preference for Diclofenac Sodium, a prescription-only NSAID, illustrates a disconnect between regulatory boundaries and consumer practices. Moreover, the perception among 30.77% of respondents that OTC drugs are entirely risk-free reflects a dangerous misconception requiring urgent public health intervention. These insights emphasise the need for targeted literacy campaigns and stronger pharmacist involvement in OTC counselling.

4.4 Digital Health & E-Pharmacy Impact

An emerging dimension of OTC drug utilisation is the rapid growth of digital health platforms and e-pharmacies. In India, platforms such as Net Meds, Pharm Easy, and Tata 1mg have transformed access to OTC products, enabling doorstep delivery and app-based purchasing. Mobile health applications increasingly guide consumers toward self-care decisions, offering symptom checkers, dosage reminders, and drug information databases.

However, this digital transformation introduces new challenges:

- **Counterfeit risks:** Online channels may facilitate the circulation of substandard or falsified medicines.
- **Reduced pharmacist interaction:** Direct-to-consumer platforms often bypass counselling, depriving patients of professional guidance.
- **Data privacy concerns:** Health apps collect sensitive consumer data, raising ethical and regulatory questions.

Despite these risks, digital health integration offers opportunities for smart packaging innovations (QR codes linking to drug information), AI-driven self-care tools, and tele-pharmacy services that could enhance safe OTC use. Regulatory authorities must therefore balance innovation with consumer protection, ensuring that digital convenience does not compromise clinical safety.

5. DISCUSSION & FUTURE VECTORS:

5.1 Pharmacist's Role in OTC Counselling

Pharmacists occupy a critical position in the safe utilisation of OTC drugs. As frontline healthcare professionals, they are uniquely positioned to guide dosage, contraindications, and potential drug-drug interactions. The World Health Organization emphasizes that pharmacists should act as "health educators" in self-medication practices, ensuring that accessibility does not compromise patient safety (WHO, 2000). In India, however, the absence of a formal OTC category and limited enforcement of counselling requirements has led to inconsistent pharmacist involvement. Strengthening pharmacist training and mandating structured counselling protocols could significantly reduce irrational self-medication.

5.2 Herbal and Nutraceutical OTC Products

The Indian market demonstrates a unique reliance on Ayurvedic and nutraceutical formulations, many of which bypass conventional pharmaceutical regulation. While these products are widely perceived as safe, evidence suggests that herbal remedies can interact with allopathic drugs, leading to adverse outcomes [12]. Globally, nutraceutical regulation varies: the United States governs dietary supplements under the Dietary Supplement Health and Education Act [14], while the European Union regulates food supplements under Directive [15]. Harmonisation of standards and transparent labelling are essential to ensure consumer safety in this rapidly expanding sector.

5.3 Economic Burden and Cost-Benefit Analysis

OTC drugs are often celebrated for reducing healthcare costs by minimising unnecessary physician visits. However, hidden costs emerge when misuse leads to complications requiring hospitalisation. For example, NSAID-related gastrointestinal bleeding, often linked to unsupervised OTC use, imposes significant financial burdens on healthcare systems [10]. A balanced cost-benefit analysis must therefore account not only for direct savings but also for the indirect costs of adverse drug events, highlighting the need for robust pharmacovigilance and consumer education.

5.4 Future Trends and Innovations

The future of OTC drug utilisation will be shaped by technological innovation and evolving consumer expectations.

- **AI-driven self-care tools**: Artificial intelligence platforms are increasingly capable of providing personalised OTC recommendations based on symptom input and medical history.
- **Smart packaging**: QR codes and digital leaflets embedded in OTC packaging can deliver real-time safety information, dosage reminders, and interaction alerts.
- **Digital health integration**: E-pharmacies and mobile health apps will continue to expand access, but regulatory safeguards must address counterfeit risks and ensure pharmacist oversight.
- **Global harmonisation**: As pharmaceutical companies pursue prescription-to-OTC switches, international collaboration will be necessary to align safety standards and labelling practices.

These innovations, if coupled with strong regulatory oversight and public health literacy campaigns, can transform OTC drugs into a safer and more effective pillar of global healthcare.

6. CONCLUSION:

Over-the-Counter (OTC) drugs have emerged as a pivotal element of modern healthcare, democratizing access to essential therapies and reducing systemic costs by alleviating the burden on formal physician consultations. Their widespread availability empowers patients to manage minor, self-limiting conditions independently, thereby optimising healthcare resource allocation. However, this accessibility is a double-edged sword: irrational self-medication, inappropriate antibiotic use, and unsafe practices among vulnerable populations continue to pose significant public health risks.

The comparative analysis of global regulatory frameworks highlights stark contrasts. The United States employs a structured dual-pathway system, modernised under the CARES Act, while the European Union emphasises harmonisation through Directive 2001/83/EC. Japan's tiered "switch OTC" model balances accessibility with pharmacist oversight, whereas Latin America struggles with enforcement gaps. India, in contrast, lacks a formal OTC category, relying instead on exclusions from statutory schedules and exploiting Ayurvedic and nutraceutical loopholes. This absence of clarity underscores the urgent need for legislative reform to establish a distinct OTC classification.

Beyond regulation, the role of pharmacists is indispensable. As frontline healthcare professionals, they must be empowered to provide structured counselling, ensure safe dosage, identify contraindications, and educate consumers about drug interactions. Simultaneously, the rise of digital health platforms and e-pharmacies has transformed consumer access, offered convenience but also introduced risks of counterfeit products, reduced professional guidance, and data privacy concerns. Harnessing these technologies responsibly—through smart packaging, AI-driven self-care tools, and tele-pharmacy services—can enhance safety while preserving accessibility.

Special populations such as children, the elderly, and pregnant women require targeted safeguards, as their physiological vulnerabilities magnify the risks of inappropriate OTC use. Furthermore, the rapid expansion of herbal and nutraceutical products demands harmonised global regulation and transparent labelling to prevent unsafe interactions with conventional medicines.

In conclusion, while OTC drugs represent a powerful instrument for expanding healthcare access, their safe integration requires a multi-pronged strategy: formalising an OTC category in India, strengthening pharmacist-led counselling, embedding pharmacovigilance systems for OTC products, regulating digital health platforms, and harmonising global standards for herbal and nutraceutical formulations. Only through such coordinated efforts can the promise of OTC drugs be fully realised—delivering affordable, accessible, and safe healthcare without compromising public health security.

REFERENCES:

1. Bhangale, V. (2007). *OTC drug marketing*. Conference on Marketing & Society, IIM Kozhikode, 397–402.
2. Anonymous. (1996). Multicenter study on self-medication and self-prescription in six Latin American countries. *Clinical Pharmacology & Therapeutics, 48*(4), 488–493.
3. Afolabi, A. O. (2008). Factors influencing the pattern of self-medication in an adult Nigerian population. *Annals of African Medicine, 7*(3), 120–127.
4. Abdelmonein, A., et al. (2005). Self-medication with antibiotics and antimalarials in Khartoum state. *Journal of Pharmacy & Pharmaceutical Sciences, 8*(2), 326–331.
5. T. J., et al. (2013). Factors contributing to the use of over-the-counter drugs and healthcare utilisation in South Korea. *Korea Health Panel Survey Report*.
6. Rekha, M. S., et al. (2015). Self-medication practices among undergraduate medical students in Bangalore. *MVJMC&RH Journal, 44*, 700–708.
7. World Health Organisation. (2000). *The role of the pharmacist in self-care and self-medication*. WHO Report.

8. World Health Organisation. (2015). *Global action plan on antimicrobial resistance*. WHO, Geneva.
9. U.S. Food and Drug Administration. (2020). *CARES Act and OTC monograph reform*. FDA.
10. European Medicines Agency. (2021). *Medicinal products regulation and pharmacovigilance in the EU*. EMA Report.
11. Pharmaceuticals and Medical Devices Agency. (2019). *Annual review*. PMDA, Tokyo.
12. Patwardhan, B., et al. (2005). Ayurveda and nutraceuticals: A global perspective. *Current Science, 89*(3), 518–524.
13. Khan, M., & Ahmed, S. (2021). E-pharmacy and digital health: Opportunities and challenges in India. *Journal of Global Health, 11*(2), 04012.
14. U.S. Congress. (1994). *Dietary Supplement Health and Education Act (DSHEA)*. Public Law 103-417.
15. European Union. (2002). *Directive 2002/46/EC on food supplements*. Official Journal of the European Communities.